or Try an Advanced Search...

    Technical Analysis for PHAT - Phathom Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    D 10.29 -0.19% -0.02
    PHAT closed down 0.19 percent on Thursday, September 28, 2023, on 88 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical PHAT trend table...
    Date Alert Name Type % Chg
    Doji - Bullish? Reversal 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    NR7 Range Contraction -0.19%
    Inside Day Range Contraction -0.19%
    Wide Bands Range Expansion -0.19%
    Oversold Stochastic Weakness -0.19%
    New Downtrend Bearish 0.29%
    Slingshot Bearish Bearish Swing Setup 0.29%
    Older End-of-Day Signals for PHAT ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    60 Minute Opening Range Breakdown about 14 hours ago
    Outside Day about 14 hours ago
    Fell Below Previous Day's Low about 14 hours ago
    Down 2 % about 14 hours ago
    Rose Above Previous Day's High about 15 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    PHAT Chart by TradingView
    Basic chart:

    Profile

    Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Life Sciences Acid Natural Sciences Medication Gastrointestinal Disorders Potassium Gastrointestinal Disease Tadataka Yamada

    Is PHAT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 26 Phathom files for FDA approval of vonoprazan for Non-Erosive GERD
    Sep 26 Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
    Aug 21 Phathom submits additional data to FDA for esophagitis candidate
    Aug 21 Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
    Aug 10 Phathom Pharmaceuticals GAAP EPS of -$0.84 beats by $0.14
    Aug 10 Phathom Pharmaceuticals Reports Second Quarter 2023 Results
    Jul 14 These 2 Biotech Stocks Are Most Likely to Be Acquired, Says Needham — and They Have Over 60% Upside Potential
    Jul 14 Phathom Pharma: Time To Take Profits (Rating Downgrade)
    Jul 10 Zacks.com featured highlights include Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies
    Jul 7 3 Top Breakout Stocks Worth a Buy for Attractive Returns
    See more PHAT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.0
    52 Week Low 5.85
    Average Volume 353,207
    200-Day Moving Average 11.32
    50-Day Moving Average 13.70
    20-Day Moving Average 12.23
    10-Day Moving Average 10.99
    Average True Range 0.72
    RSI (14) 23.66
    ADX 28.62
    +DI 9.67
    -DI 29.74
    Chandelier Exit (Long, 3 ATRs) 12.69
    Chandelier Exit (Short, 3 ATRs) 12.16
    Upper Bollinger Bands 15.11
    Lower Bollinger Band 9.35
    Percent B (%b) 0.16
    BandWidth 47.12
    MACD Line -1.06
    MACD Signal Line -0.86
    MACD Histogram -0.2029
    Fundamentals Value
    Market Cap 266.68 Million
    Num Shares 25.9 Million
    EPS -10.08
    Price-to-Earnings (P/E) Ratio -1.02
    Price-to-Sales 0.00
    Price-to-Book 7.53
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.08
    Resistance 3 (R3) 11.07 10.81 10.95
    Resistance 2 (R2) 10.81 10.61 10.81 10.90
    Resistance 1 (R1) 10.55 10.48 10.68 10.55 10.86
    Pivot Point 10.28 10.28 10.35 10.28 10.28
    Support 1 (S1) 10.02 10.08 10.15 10.03 9.72
    Support 2 (S2) 9.76 9.96 9.76 9.68
    Support 3 (S3) 9.50 9.76 9.63
    Support 4 (S4) 9.50